Scarica l'app Stockscreener
94.81
1.27%
-1.19
Dopo l'orario di chiusura:
94.81
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché BNTX Giù?
Forum
Previsione
Storia dei dividendi
Biontech Se Adr Borsa (BNTX) Ultime notizie
Berenberg Bank Issues Positive Forecast for BioNTech (NASDAQ:BNTX) Stock Price - Defense World
Amundi Lowers Stake in BioNTech SE Sponsored ADR $BNTX - Defense World
Altrinsic Global Advisors LLC Sells 123,995 Shares of BioNTech SE Sponsored ADR $BNTX - Defense World
First Trust Advisors LP Has $35.28 Million Holdings in BioNTech SE Sponsored ADR $BNTX - Defense World
BioNTech: Maintaining "Strong Buy" After Part 1 Success Of Next-Gen Anti-CTLA-4 Gotistobart - Seeking Alpha
BioNTech-Bristol Drug Shows Hope For Breast Cancer Patients With Few Options - Benzinga
DoorDash Upgraded, Microsoft Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
BioNTech stock rises after promising lung cancer drug shows survival benefit By Investing.com - Investing.com South Africa
BioNTech stock rises after promising lung cancer drug shows survival benefit - Investing.com
Dodge & Cox Invests $93.42 Million in BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech’s (BNTX) “Buy” Rating Reaffirmed at Jefferies Financial Group - Defense World
Regulatory Storm Hits BioNTech as FDA Memo Sparks Sector-Wide Anxiety () - aktiencheck.de
Vaccine Stocks Fall After FDA Plans to Impose Stricter Vaccine Rules - Yahoo Finance
Scotia Capital Inc. Cuts Stock Position in BioNTech SE Sponsored ADR $BNTX - MarketBeat
Validea's Top Health Care Stocks Based On Benjamin Graham12/1/2025 - Nasdaq
Groupama Asset Managment Buys 26,681 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
Employees Retirement System of Texas Has $1.69 Million Position in BioNTech SE Sponsored ADR $BNTX - MarketBeat
Legal & General Group Plc Boosts Stock Position in BioNTech SE Sponsored ADR $BNTX - MarketBeat
Aristides Capital LLC Purchases 2,826 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech SE ADR Rises 3.0%, Outperforms Market - 富途牛牛
Edmond DE Rothschild Holding S.A. Raises Stock Position in BioNTech SE Sponsored ADR $BNTX - MarketBeat
BioNTech’s acquisition of CureVac nears completion as offer deadline approaches - Investing.com
BioNTech SE Sponsored ADR $BNTX Shares Purchased by CenterBook Partners LP - MarketBeat
AXQ Capital LP Acquires 1,073 Shares of Strategy Inc $MSTR - Defense World
Bank Julius Baer & Co. Ltd Zurich Lowers Stock Holdings in BioNTech SE Sponsored ADR $BNTX - Defense World
Allworth Financial LP Grows Stake in BioNTech SE Sponsored ADR $BNTX - Defense World
Pfizer Is Giving Up on BioNTech. Should You Ditch BNTX Stock Now Too? - Barchart.com
BioNTech Faces Strategic Crossroads as Pfizer Reduces Stake () - aktiencheck.de
Total debt per share of BioNTech SE Sponsored ADR – BER:22UA - TradingView
SG Americas Securities LLC Acquires 51,792 Shares of BioNTech SE Sponsored ADR $BNTX - MarketBeat
BMY Stock Down on Discontinuation of ACS Clinical Study With JNJ - Finviz
BioNTech’s Earnings Call: Progress Amid Challenges - MSN
Pfizer Scales Back Major Stake in BioNTech - Ad-hoc-news.de
BioNTech Shares Under Pressure as Key Investor Exits - AD HOC NEWS
Allianz SE Buys 5,080 Shares of BioNTech SE Sponsored ADR $BNTX - Defense World
BioNTech Shares Face Pressure as Pfizer Cuts Stake () - aktiencheck.de
Pfizer sheds BioNTech stake years after blockbuster COVID vaccine tie-up By Reuters - Investing.com
BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Is BioNTech Stock Building Momentum for a Sustained Recovery? () - aktiencheck.de
BioNTech SE (BNTX) Stock Price, Trades & News - GuruFocus
BioNTech SE Reports Q3 2025 Financial Results - MSN
BioNTech Earnings: Steady Progress in Next-Generation Oncology Pipeline; Guidance Raised - Morningstar
BioNTech’s Promising Clinical Study: A New Hope for Advanced Solid Tumors? - MSN
BioNTech Faces Critical Earnings Test Amid Divergent Forecasts () - aktiencheck.de
BioNTech SE’s Promising Phase 3 Study on NSCLC Treatment: A Potential Game-Changer - TipRanks
BioNTech’s BNT327: A Promising New Approach in Breast Cancer Treatment - MSN
BioNTech’s BNT116 Study: A New Hope for Advanced Lung Cancer? - MSN
BioNTech’s Promising PDAC Study: Market Implications and Progress - MSN
BioNTech’s Latest Clinical Study: A New Hope for Advanced Solid Tumors? - TipRanks
ETFs Investing in BioNTech SE Sponsored ADR Stocks - TradingView
3.27%
0.93%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):